000			01956 a2200601 4500
005			20250516193151.0
264		0	_c20150207
008			201502s 0 0 eng d
022			_a1573-0646
024	7		_a10.1007/s10637-014-0066-9 _2doi
040			_aNLM _beng _cNLM
100	1		_aHaas, N B
245	0	0	_aPhase II trial of vorinostat in advanced melanoma. _h[electronic resource]
260			_bInvestigational new drugs _cJun 2014
300			_a526-34 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aBiomarkers _xblood
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aFibroblast Growth Factors _xblood
650	0	4	_aHistone Deacetylase Inhibitors _xadverse effects
650	0	4	_aHistones _xmetabolism
650	0	4	_aHumans
650	0	4	_aHydroxamic Acids _xadverse effects
650	0	4	_aMale
650	0	4	_aMelanoma _xdrug therapy
650	0	4	_aMiddle Aged
650	0	4	_aPolymorphism, Single Nucleotide
650	0	4	_aSkin Neoplasms
650	0	4	_aTumor Suppressor Protein p53 _xgenetics
650	0	4	_aVascular Endothelial Growth Factor A _xblood
650	0	4	_aVorinostat
650	0	4	_aMelanoma, Cutaneous Malignant
700	1		_aQuirt, I
700	1		_aHotte, S
700	1		_aMcWhirter, E
700	1		_aPolintan, R
700	1		_aLitwin, S
700	1		_aAdams, P D
700	1		_aMcBryan, T
700	1		_aWang, L
700	1		_aMartin, L P
700	1		_avonMehren, M
700	1		_aAlpaugh, R K
700	1		_aZweibel, J
700	1		_aOza, A
773	0		_tInvestigational new drugs _gvol. 32 _gno. 3 _gp. 526-34
856	4	0	_uhttps://doi.org/10.1007/s10637-014-0066-9 _zAvailable from publisher's website
999			_c23486120 _d23486120